title: A randomized, prospective, two-center comparison of sirolimus-eluting stent and zotarolimus-eluting stent in acute ST-elevation myocardial infarction: the SEZE trial.
abstract: BACKGROUND
  The zotarolimus-eluting stent has shown larger in-stent late lumen loss compared to sirolimus-eluting stents in previous studies. However, this has not been thoroughly evaluated in ST elevation myocardial infarction.
  
  
  METHODS
  This was a prospective, randomized, controlled trial evaluating angiographic outcomes in patients presenting with ST elevation myocardial infarction, treated with zotarolimus-eluting stents or sirolimus-eluting stents. From March 2007 to February 2009, 122 patients were randomized to zotarolimus-eluting stents or sirolimus-eluting stents in a 1:1 fashion. The primary endpoint was 9-month in-stent late lumen loss confirmed by coronary angiography, and secondary endpoints were percent diameter stenosis, binary restenosis rate, major adverse cardiac events (a composite of cardiac death, non-fatal myocardial infarction, and target vessel revascularization), and late-acquired incomplete stent apposition.
  
  
  RESULTS
  Angiographic in-stent late lumen loss was significantly higher in the zotarolimus-eluting stent group compared to the sirolimus-eluting stent group ((0.49 ± 0.65) mm vs. (0.10 ± 0.46) mm, P = 0.001). Percent diameter stenosis at 9-month follow-up was also larger in the zotarolimus-eluting stent group ((30.0 ± 17.9)% vs. (17.6 ± 14.0)%, P < 0.001). In-segment analysis showed similar findings. There were no significant differences in binary restenosis rate, major adverse cardiac events, and late-acquired incomplete stent apposition.
  
  
  CONCLUSIONS
  Compared to sirolimus-eluting stents, the zotarolimus-eluting stent is associated with significantly higher in-stent late lumen loss at 9-month angiographic follow-up in the treatment of ST elevation myocardial infarction. Although there was no significant difference in 1-year clinical outcomes, the clinical implication of increased late lumen loss should be further studied.
authors.affiliation: Seoul National University Boramae Hospital, Seoul, South Korea.
authors.forename: Woo-Young
authors.initials: WY
authors.lastname: Chung
authors.forename: Jeehoon
authors.initials: J
authors.lastname: Kang
authors.forename: Young-Seok
authors.initials: YS
authors.lastname: Cho
authors.forename: Hae-Jun
authors.initials: HJ
authors.lastname: Park
authors.forename: Han-Mo
authors.initials: HM
authors.lastname: Yang
authors.forename: Jae-Bin
authors.initials: JB
authors.lastname: Seo
authors.forename: Jung-Won
authors.initials: JW
authors.lastname: Suh
authors.forename: Kwang-Il
authors.initials: KI
authors.lastname: Kim
authors.forename: Tae-Jin
authors.initials: TJ
authors.lastname: Youn
authors.forename: Sang-Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: In-Ho
authors.initials: IH
authors.lastname: Chae
authors.forename: Joo-Hee
authors.initials: JH
authors.lastname: Zo
authors.forename: Myung-A
authors.initials: MA
authors.lastname: Kim
authors.forename: Dong-Ju
authors.initials: DJ
authors.lastname: Choi
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: C489443:zotarolimus; D020123:Sirolimus